Moderna, the biotechnology company behind one of two mRNA-based vaccines currently being distributed worldwide for the COVID-19 pandemic, has announced that it will develop new mRNA vaccines for three viruses. Possible vaccines include HIV, seasonal flu and Nipah virus. Moderna's development and clinical trial for the COVID-19 vaccine is one of the fastest in the history of vaccines and so far its results are very promising.
An mRNA vaccine is different from standard, conventional vaccines. What this vaccine does is to give instructions on how to create specific proteins that will trigger the body's natural defenses. MRNA instructions, which are temporary and do not affect the real thing DNA simply push the body’s cells to produce proteins that reflect those used by a virus for attachment and contamination of cells. The independent proteins are then fought by one's natural immune response person, which provides an ongoing lesson on how to fight off future proteins that match this profile, including those that help viruses attach and infect humans.
Moderna's new programs target not only seasonal flu, but also a combination vaccine that could target both the regular flu and COVID-2, the virus leading to COVID-19. The candidate vaccine for HIV developed in collaboration with AIDS Vaccine Initiative and the Bill and Melinda Gates Foundation, are expected to enter the first phase of clinical trials later this year. Nipah virus is an extremely deadly disease that can cause respiratory and neurological symptoms and is a particular threat to IndiaThe Bangladesh, Malaysia and Singapore.
Indeed, mRNA-based vaccines provide greater flexibility as they do not use an active or inactive virus, reducing the risk of causing immediate infections. The COVID-19 pandemic caused significant investments to all of them technological fields and one of them is vaccines using new mRNA technology.
Source of information: techcrunch.com